BR112022021957A2 - Imidazopirimidinas como moduladores de il -17 - Google Patents
Imidazopirimidinas como moduladores de il -17Info
- Publication number
- BR112022021957A2 BR112022021957A2 BR112022021957A BR112022021957A BR112022021957A2 BR 112022021957 A2 BR112022021957 A2 BR 112022021957A2 BR 112022021957 A BR112022021957 A BR 112022021957A BR 112022021957 A BR112022021957 A BR 112022021957A BR 112022021957 A2 BR112022021957 A2 BR 112022021957A2
- Authority
- BR
- Brazil
- Prior art keywords
- imidazopyrimidines
- modulators
- ameliorate
- syndrome
- treat
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Fats And Perfumes (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063017679P | 2020-04-30 | 2020-04-30 | |
| PCT/IB2021/053517 WO2021220183A1 (en) | 2020-04-30 | 2021-04-28 | Imidazopyrimidines as modulators of il-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022021957A2 true BR112022021957A2 (pt) | 2023-01-17 |
Family
ID=75769661
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022021957A BR112022021957A2 (pt) | 2020-04-30 | 2021-04-28 | Imidazopirimidinas como moduladores de il -17 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US12559496B2 (https=) |
| EP (1) | EP4143193B1 (https=) |
| JP (1) | JP7661361B2 (https=) |
| KR (1) | KR20230018387A (https=) |
| CN (1) | CN115867348B (https=) |
| AU (1) | AU2021262588A1 (https=) |
| BR (1) | BR112022021957A2 (https=) |
| CA (1) | CA3181793A1 (https=) |
| IL (1) | IL297734A (https=) |
| MX (1) | MX2022013650A (https=) |
| WO (1) | WO2021220183A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201909190D0 (en) | 2019-06-26 | 2019-08-07 | Ucb Biopharma Sprl | Therapeutic agents |
| WO2023025783A1 (en) | 2021-08-23 | 2023-03-02 | Leo Pharma A/S | Small molecule modulators of il-17 |
| WO2023111181A1 (en) | 2021-12-16 | 2023-06-22 | Leo Pharma A/S | Small molecule modulators of il-17 |
| WO2023166172A1 (en) | 2022-03-04 | 2023-09-07 | Leo Pharma A/S | Small molecule modulators of il-17 |
| TW202430165A (zh) | 2022-12-02 | 2024-08-01 | 丹麥商理奧藥品公司 | Il-17之小分子調節劑 |
| CN121311483A (zh) * | 2023-03-28 | 2026-01-09 | 詹森药业有限公司 | 含内酰胺的咪唑并哒嗪il-17抑制剂化合物 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9284283B2 (en) * | 2012-02-02 | 2016-03-15 | Ensemble Therapeutics Corporation | Macrocyclic compounds for modulating IL-17 |
| GB201321736D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
| EP3080131B1 (en) * | 2013-12-10 | 2018-10-10 | Bristol-Myers Squibb Company | Imidazopyridazine compounds useful as modulators of il-12, il-23 and/or ifn alpha responses |
| MA40759A (fr) * | 2014-09-26 | 2017-08-01 | Pfizer | Modulateurs de rorc2 de type pyrrolopyridine substitué par un méthyle et trifluorométhyle et leurs procédés d'utilisation |
| US10152431B2 (en) | 2015-03-16 | 2018-12-11 | Honeywell International Inc. | System and method for remote set-up and adjustment of peripherals |
| US10479793B2 (en) * | 2015-11-18 | 2019-11-19 | Bristol-Myers Squibb Company | Imidazopyridazine compounds useful as modulators of IL-12, IL-23 and/or IFN alpha responses |
| GB201709456D0 (en) * | 2017-06-14 | 2017-07-26 | Ucb Biopharma Sprl | Therapeutic agents |
| WO2019138017A1 (en) * | 2018-01-15 | 2019-07-18 | Ucb Biopharma Sprl | Fused imidazole derivatives as il-17 modulators |
| WO2019223718A1 (zh) | 2018-05-22 | 2019-11-28 | 成都先导药物开发股份有限公司 | 一种免疫调节剂 |
| IL279348B2 (en) * | 2018-06-15 | 2026-01-01 | Reata Pharmaceuticals Inc | Decahydro-2h-naphth[1,2-d]imidazole compounds for inhibition of IL-17 and ROR-gamma |
| JP7349491B2 (ja) * | 2018-07-12 | 2023-09-22 | ユーシービー バイオファルマ エスアールエル | Ｉｌ－１７モジュレーターとしてのスピロ環状インダン類似体 |
| KR20230019507A (ko) * | 2020-04-30 | 2023-02-08 | 얀센 파마슈티카 엔.브이. | Il-17의 조절제로서의 이미다조피리다진 |
| MX2022013637A (es) | 2020-04-30 | 2022-11-16 | Janssen Pharmaceutica Nv | Nuevos compuestos de triazinoindol. |
| MX2022013649A (es) | 2020-04-30 | 2023-02-01 | Janssen Pharmaceutica Nv | Métodos para identificar moduladores de la ruta de il-17. |
-
2021
- 2021-04-28 WO PCT/IB2021/053517 patent/WO2021220183A1/en not_active Ceased
- 2021-04-28 US US17/997,437 patent/US12559496B2/en active Active
- 2021-04-28 IL IL297734A patent/IL297734A/en unknown
- 2021-04-28 CA CA3181793A patent/CA3181793A1/en active Pending
- 2021-04-28 AU AU2021262588A patent/AU2021262588A1/en not_active Abandoned
- 2021-04-28 MX MX2022013650A patent/MX2022013650A/es unknown
- 2021-04-28 JP JP2022566012A patent/JP7661361B2/ja active Active
- 2021-04-28 BR BR112022021957A patent/BR112022021957A2/pt not_active Application Discontinuation
- 2021-04-28 CN CN202180047235.4A patent/CN115867348B/zh active Active
- 2021-04-28 EP EP21723010.1A patent/EP4143193B1/en active Active
- 2021-04-28 KR KR1020227041944A patent/KR20230018387A/ko not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| EP4143193A1 (en) | 2023-03-08 |
| WO2021220183A1 (en) | 2021-11-04 |
| CN115867348B (zh) | 2025-05-06 |
| KR20230018387A (ko) | 2023-02-07 |
| EP4143193B1 (en) | 2026-04-22 |
| IL297734A (en) | 2022-12-01 |
| CN115867348A (zh) | 2023-03-28 |
| MX2022013650A (es) | 2023-02-01 |
| JP2023523770A (ja) | 2023-06-07 |
| JP7661361B2 (ja) | 2025-04-14 |
| AU2021262588A1 (en) | 2023-01-19 |
| US20230242537A1 (en) | 2023-08-03 |
| CA3181793A1 (en) | 2021-11-04 |
| US12559496B2 (en) | 2026-02-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022021957A2 (pt) | Imidazopirimidinas como moduladores de il -17 | |
| BR112022021962A2 (pt) | Imidazopiridazinas como moduladores de il-17 | |
| EA202191630A1 (ru) | ХИМИЧЕСКИ МОДИФИЦИРОВАННЫЕ КОНСТРУКЦИИ ДЛЯ RNAi И ПУТИ ИХ ПРИМЕНЕНИЯ | |
| JOP20230124A1 (ar) | تضفير مترافقات عقار جسم مضاد معدل وطرق استخدامها | |
| MX2020010999A (es) | Moduladores de enzimas modificadoras de metilo, composiciones y usos de estos. | |
| BR112022000231A2 (pt) | Novos métodos | |
| BR112015009624A2 (pt) | inibidores de tirosina cinase de bruton | |
| CY1122565T1 (el) | Συνθεσεις και μεθοδοι μη χειρουργικης θεραπειας βλεφαροπτωσης | |
| BR112014026176A2 (pt) | dipiridilaminas substituídas e usos das mesmas | |
| EA201200406A1 (ru) | Соединения и композиции, которые являются модуляторами активности tlr | |
| CY1109877T1 (el) | Αντισωματα εναντι αμυλοειδους-βητα πεπτιδιου | |
| BR112017007662A2 (pt) | composto, composição farmacêutica, processo de elaboração de uma composição farmacêutica, método de tratamento de distúrbio ou doença relativa a er, kit de tratamento e uso de composto | |
| DK2459216T3 (da) | Immunogene sammensætninger omfattende tlr-aktivitetsmodulatorer | |
| BR112017026057A2 (pt) | profármacos constituídos por um conjugado linker de ácido hialurônico e agonista duplo de glp-1/glucagon | |
| BRPI0610850A2 (pt) | derivados de Ácido aril alquila, composiÇço farmacÊutica, medicamento, bem como uso dos referidos derivados | |
| BR112014011850A2 (pt) | derivados de aminopirimidina como moduladores de lrrk2 | |
| BR112015020389A8 (pt) | compostos carbazol úteis como inibidores de bromodomínio, seu uso, bem como composição e produto farmacêuticos compreendendo os mesmos | |
| BR112017009647A2 (pt) | 2-amino-3,5-difluoro-3,6-dimetil-6-fenil-3,4,5,6-tetraidropiridinas como inibidoras da bace1 para tratar a doença de alzheimer | |
| BR112019001253A2 (pt) | composto, composição farmacêutica, e, métodos de tratamento de câncer ou de atrofia muscular e de doença de parkinson. | |
| BR112014023384A8 (pt) | inibidores de bace espirocíclicos de di-hidro-tiazina e di-hidro-oxazina, e composições e usos dos mesmos. | |
| BR112014003704A2 (pt) | moduladores ror gama | |
| UY39958A (es) | Compuestos de imidazopiridazina inhibidores de il-17 | |
| MX374749B (es) | Terapia de combinacion que comprende un inhibidor de tor cinasa y un analogo de citidina para tratar cancer. | |
| UY39957A (es) | Compuestos de imidazopiridazina inhibidores de il-17 | |
| BR112016027043A8 (pt) | combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
| B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |